中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.017 seconds)

    Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
    21.
    发明申请
    Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product 有权

    公开(公告)号：US20100247620A1

    公开(公告)日：2010-09-30

    申请号：US12384007

    申请日：2009-03-31

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K9/127 ,  A61P35/00

    CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K31/4745 ,  A61K45/06 ,  A61K2300/00

    Abstract: This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3′-end of the broken DNA. Tyrosyl-DNA phosphodiesterase (Tdp1) can repair Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. Inhibiting Tdp1 has the potential to enhance the anticancer activity of Top1 inhibitors and to act as antiproliferative agents. It has been recently reported that neomycin inhibits Tdp1 more effectively than the related aminoglycosides paromomycin and lividomycin A. Inhibition of Tdp1 by neomycin is observed both with single- and double-stranded substrates but is slightly stronger with duplex DNA, which is different from aclarubicin, which only inhibits Tdp1 with the double-stranded substrate. Inhibition by neomycin can be overcome with excess Tdp1 and is greatest at low pH. Aminoglycoside antibiotics and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first reported pharmacological Tdp1 inhibitors. The development of Tdp1 inhibitors as anticancer agents can be envisioned as combinations of Tdp1 and Top1 inhibitors. Moreover, Tdp1 inhibitors might also be effective by themselves as anticancer agents. In addition, Tdp1 inhibitors might be valuable as anti-infectious agents.This invention can produce a co-encapsulated combination drug product consisting of a topoisomerase 1 inhibitor such as camptothecins including neat camptothecin and its derivatives irinotecan, topotecan and other derivatives, and a tyrosyl-DNA phosphodiesterase (Tdp1) such as aminoglycoside antibiotics including neomycin and tetracycline, and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin.

    Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
    22.
    发明申请
    Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency 审中-公开
    组合疗法包括使用蛋白激酶C调节剂和组蛋白脱乙酰酶抑制剂来治疗HIV-1潜伏期

    公开(公告)号：US20100166806A1

    公开(公告)日：2010-07-01

    申请号：US12317758

    申请日：2008-12-29

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K9/00 ,  A61K31/366 ,  A61K31/19 ,  A61P31/18 ,  C07D493/22 ,  A61K31/165

    CPC classification number: A61K31/165 ,  A61K31/19 ,  A61K31/366 ,  C07D493/22

    Abstract: The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).

    Abstract translation: 本发明涉及治疗的组合，更具体地涉及HIV-1感染的组合治疗。 本发明涉及使用苔藓抑制因子-1及其天然和合成衍生物用于艾滋病治疗，特别是使用苔藓素与其它活性药物如组蛋白脱乙酰酶（HDAC）抑制剂和抗逆转录病毒药物组合使用，用于 治疗HIV-1潜伏期。 根据本发明，我们提供了用于治疗HIV-1潜伏期的组合疗法，其采用苔藓抑制因子-1（和类似物）和以下HDAC抑制剂之一; 丙戊酸，丁酸酯衍生物，异羟肟酸和苯甲酰胺。 虽然HDACi可以用于连续给药方案，但是可以按循环给药方案使用倍性抑素。 苔藓抑菌素可以配制在药物可接受的载体中，包括纳米颗粒，磷脂纳米体和/或可生物降解的聚合物纳米球。 这种联合治疗需要用于用抗逆转录病毒治疗（HIV-1蛋白酶抑制剂，HIV-1逆转录酶抑制剂，HIV-1整合酶抑制剂，CCR5辅助受体抑制剂和融合抑制剂）治疗的患者。

    TERMINAL STERILIZATION OF BIOLOGICS
    25.
    发明申请
    TERMINAL STERILIZATION OF BIOLOGICS 有权

    公开(公告)号：US20220111082A1

    公开(公告)日：2022-04-14

    申请号：US17499836

    申请日：2021-10-12

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61L2/00 ,  B01F5/04

    Abstract: The invention involves the use of supercritical or near supercritical fluids to inactivate pathogens in biologic materials which may or may not be contaminated by pathogens. The pathogen reduced material is then inserted into empty, sterile containment vessels. The apparatus can be used as a means to achieve terminal sterilization of the biologic materials. The preferred method of use for the apparatus includes operation of a conveyor belt to move and fill bottles, flasks, containers, or vials in an assembly line to create the finished product in an effective and timely fashion.

    Apparatus and methods for making nanosomes loaded with nucleic acid
    28.
    发明授权
    Apparatus and methods for making nanosomes loaded with nucleic acid 有权

    公开(公告)号：US09981238B2

    公开(公告)日：2018-05-29

    申请号：US13216079

    申请日：2011-08-23

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: B01J13/04 ,  A61K9/127 ,  A61K31/713 ,  B82Y5/00 ,  C12N15/88

    CPC classification number: B01J13/04 ,  A61K9/127 ,  A61K9/1277 ,  A61K31/713 ,  B82Y5/00 ,  C12N15/88

    Abstract: Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a supercritical, critical or near critical fluid. The apparatus further comprises injection means in fluid communication with said first containment means for receiving the mixture and releasing the mixture as a stream into a decompression liquid. The apparatus further comprises a decompression vessel in fluid communication with the injection means for holding a decompression liquid and receiving the mixture as a stream. The stream forms one or more nanosomes loaded with a nucleic acid in the decompression liquid.

    Methods and apparatus for processing cellulosic biomass
    29.
    发明授权
    Methods and apparatus for processing cellulosic biomass 有权
    处理纤维素生物质的方法和装置

    公开(公告)号：US08540847B2

    公开(公告)日：2013-09-24

    申请号：US13198355

    申请日：2011-08-04

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: D21F1/66 ,  C12P7/52

    CPC classification number: D21C3/22 ,  D21C1/10 ,  D21C3/20 ,  D21C11/0007 ,  Y02E50/16

    Abstract: Embodiments of the present invention are directed to apparatus and methods for the substantially continuous processing of cellulosic biomasses with a supercritical, critical or near critical fluid to produce ethanol, bio-fuels and high value end products.

    Abstract translation: 本发明的实施方案涉及用于具有超临界，临界或近临界流体以生产乙醇，生物燃料和高价值终产物的纤维素生物质的基本上连续加工的装置和方法。

    CHRONIC INFLAMMATION AND TRANSPLANTATION
    30.
    发明申请
    CHRONIC INFLAMMATION AND TRANSPLANTATION 审中-公开
    慢性炎症和转移

    公开(公告)号：US20120309818A1

    公开(公告)日：2012-12-06

    申请号：US13355256

    申请日：2012-01-20

    Applicant: Jonathan Steven ALEXANDER ,  April C. Carpenter ,  Trevor Percival Castor

    Inventor： Jonathan Steven ALEXANDER ,  April C. Carpenter ,  Trevor Percival Castor

    IPC: A61K31/365 ,  C07D493/22 ,  A61P29/00

    CPC classification number: A61K31/365

    Abstract: Embodiments of the present invention feature methods for treating inflammatory disease and transplantation characterized in that it includes: (i) the incubation of organs with one or more Bryostatin-1 derivatives under conditions which permits vascular exposure to these compounds prior to or immediately following organ ‘harvesting’, and (ii) intravenous, transdermal, intraperitoneal, intra-alveolar instillation of Bryostatin-1 in vivo during active disease, or during periods of disease remission and (iii) prophylactic administration of Bryostatin-1 to limit the development of GVHD.

    Abstract translation: 本发明的实施方案的特征在于治疗炎性疾病和移植的方法，其特征在于其包括：（i）在器官收获之前或之后容许血管暴露于这些化合物的条件下，将器官与一种或多种苔藓抑制素-1衍生物一起孵育 ，和（ii）在活动性疾病期间或在疾病缓解期间静脉内，经皮，腹膜内，肺泡内滴注苔藓抑制因子-1，和（iii）预防性施用苔藓抑制因子-1以限制GVHD的发展。

Patent Agency Ranking